Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nobumichi Tanaka

Showing results (1-10 of 290) with videos related to

Pageof 29
Sort By:
Prostate International|September 25, 2023
The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancerNobumichi Tanaka
Hinyokika Kiyo. Acta Urologica Japonica|September 17, 2005
[Partial nephrectomy for renal cell carcinoma using a microwave tissue coagulator--postoperative recurrence and renal function]Kiyohide Fujimoto, Nobumichi Tanaka, Yoshihiko Hirao
Brachytherapy|December 3, 2014
Urethral toxicity after LDR brachytherapy: experience in JapanNobumichi Tanaka, Isao Asakawa, Masatoshi Hasegawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 25, 2019
Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in JapanNobumichi Tanaka, Isao Asakawa, Masatoshi Hasegawa, et al.
Pathology International|February 25, 2012
Phyllodes tumor of the prostateTomomi Fujii, Keiji Shimada, Nobumichi Tanaka, et al.
Japanese Journal of Clinical Oncology|March 20, 2010
Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG dataNobumichi Tanaka, Kiyohide Fujimoto, Akihide Hirayama, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|December 4, 2009
Phosphorylation status of Fas-associated death domain-containing protein regulates telomerase activity and strongly correlates with prostate cancer outcomesYoshiaki Matsumura, Keiji Shimada, Nobumichi Tanaka, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 3, 2008
Prognostic factors of renal cell carcinoma with extension into inferior vena cavaMasahiro Tanaka, Kiyohide Fujimoto, Eijiro Okajima, et al.
Hormones & Cancer|May 31, 2015
A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. BicalutamideYasushi Nakai, Nobumichi Tanaka, Satoshi Anai, et al.
The Journal of Pathology|February 20, 2014
Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cellsKeiji Shimada, Satoshi Anai, Tomomi Fujii, et al.
Pageof 29

Showing results (1-10 of 290) with videos related to

Sort By:
Pageof 29
Prostate International|September 25, 2023
The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancerNobumichi Tanaka
Hinyokika Kiyo. Acta Urologica Japonica|September 17, 2005
[Partial nephrectomy for renal cell carcinoma using a microwave tissue coagulator--postoperative recurrence and renal function]Kiyohide Fujimoto, Nobumichi Tanaka, Yoshihiko Hirao
Brachytherapy|December 3, 2014
Urethral toxicity after LDR brachytherapy: experience in JapanNobumichi Tanaka, Isao Asakawa, Masatoshi Hasegawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 25, 2019
Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in JapanNobumichi Tanaka, Isao Asakawa, Masatoshi Hasegawa, et al.
Pathology International|February 25, 2012
Phyllodes tumor of the prostateTomomi Fujii, Keiji Shimada, Nobumichi Tanaka, et al.
Japanese Journal of Clinical Oncology|March 20, 2010
Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG dataNobumichi Tanaka, Kiyohide Fujimoto, Akihide Hirayama, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|December 4, 2009
Phosphorylation status of Fas-associated death domain-containing protein regulates telomerase activity and strongly correlates with prostate cancer outcomesYoshiaki Matsumura, Keiji Shimada, Nobumichi Tanaka, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 3, 2008
Prognostic factors of renal cell carcinoma with extension into inferior vena cavaMasahiro Tanaka, Kiyohide Fujimoto, Eijiro Okajima, et al.
Hormones & Cancer|May 31, 2015
A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. BicalutamideYasushi Nakai, Nobumichi Tanaka, Satoshi Anai, et al.
The Journal of Pathology|February 20, 2014
Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cellsKeiji Shimada, Satoshi Anai, Tomomi Fujii, et al.
Pageof 29